2-Methoxyestradiol Completed Phase 2 Trials for Metastatic Renal Cell Carcinoma ( mRCC) Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00444314Phase 2 Study of Panzem® NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma